Accelerating AI-Driven Drug Discovery
Anthropic Acquires Coefficient Bio for $400 Million
The AI leader expands into life sciences to accelerate drug discovery and R&D planning.
A professional laboratory setting with a high-resolution display showing a colorful 3D molecular structure used for drug discovery.
Photo: Kronos Digital News
Anthropic has acquired the stealth-mode biotech startup Coefficient Bio for approximately $400 million [1]. This move aims to deepen the company's footprint in the life sciences sector [1]. Anthropic will integrate the startup's tools to accelerate drug discovery and research development [1][3]. Coefficient Bio is a small firm with fewer than 10 employees [2]. Despite its size, the startup provides critical expertise for specialized pharmaceutical R&D [1]. This acquisition demonstrates the increasing value of AI applications in advanced biological sciences [3].
Editorial notes
Transparency note
Drafted with LLM; human-edited
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
biospace.com
https://www.biospace.com/business/ai-giant-anthropic-leans-into-life-sciences-with-400m-coefficient-bio-catch
- 2.↗
thenextweb.com
https://thenextweb.com/news/anthropic-just-paid-400-million-for-a-startup-with-fewer-than-10-people
- 3.↗
oncodaily.com
https://oncodaily.com/techology/anthropic479262
Related stories
View all
Topics
About the author
Kronos Digital News Desk covers accelerating ai-driven drug discovery and editorial analysis for Kronos Digital News.